05 Mar 2011
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and its U.S. subsidiary Eisai Inc. announced that the United States Food and Drug Administration (FDA) approved the company's anti-epileptic agent BANZEL® (rufinamide) Oral Suspension, 40 mg/ml on March 3 (U.S. local time) for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children 4 years and older and adults. The oral suspension formulation is bioequivalent to the currently marketed BANZEL® tablet formulation on a milligram per milligram basis and will be available in the United States for prescription use by late March 2011.Read the rest of the article here.
No comments:
Post a Comment